Omicron severity: milder but not mild
- PMID: 35065007
- PMCID: PMC8769661
- DOI: 10.1016/S0140-6736(22)00056-3
Omicron severity: milder but not mild
Conflict of interest statement
BJC reports honoraria from AstraZeneca, GSK, Moderna, Roche, and Sanofi, outside the area of work commented on here. JN was previously employed by, and owns shares in, Sanofi, outside the area of work commented on here. We thank Julie Au for technical assistance.
Comment on
-
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19. Lancet. 2022. PMID: 35065011 Free PMC article.
References
-
- UK Health Security Agency SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: update on hospitalisation and vaccine effectiveness for omicron VOC-21NOV-01 (B.1.1.529) Dec 31, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
-
- Madhi SA, Kwatra G, Myers JE, et al. South African population immunity and severe Covid-19 with omicron variant. medRxiv. 2021 doi: 10.1101/2021.12.20.21268096. published online Dec 21. (preprint). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical